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Abstract
Nocodazole is a known destabiliser of microtubule dynamics and arrests cell-cycle at the G2/M phase. In the context of the
human embryonic stem cell (hESC) it is important to understand how this arrest influences the pluripotency of cells. Here
we report for the first time the changes in the expression of transcription markers Nanog and Oct4 as well as SSEA-3 and
SSEA-4 in human embryonic cells after their treatment with nocodazole. Multivariate permeabilised-cell flow cytometry was
applied for characterising the expression of Nanog and Oct4 during different cell cycle phases. Among untreated hESC we
detected Nanog-expressing cells, which also expressed Oct4, SSEA-3 and SSEA-4. We also found another population
expressing SSEA-4, but without Nanog, Oct4 and SSEA-3 expression. Nocodazole treatment resulted in a decrease of cell
population positive for all four markers Nanog, Oct4, SSEA-3, SSEA-4. Nocodazole-mediated cell-cycle arrest was
accompanied by higher rate of apoptosis and upregulation of p53. Twenty-four hours after the release from nocodazole
block, the cell cycle of hESC normalised, but no increase in the expression of transcription markers Nanog and Oct4 was
detected. In addition, the presence of ROCK-2 inhibitor Y-27632 in the medium had no effect on increasing the expression
of pluripotency markers Nanog and Oct4 or decreasing apoptosis or the level of p53. The expression of SSEA-3 and SSEA-4
increased in Nanog-positive cells after wash-out of nocodazole in the presence and in the absence of Y-27632. Our data
show that in hESC nocodazole reversible blocks cell cycle, which is accompanied by irreversible loss of expression of
pluripotency markers Nanog and Oct4.
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Introduction
Human embryonic stem cells (hESC) are characterised by
pluripotency, unlimited proliferative growth potential and a
short cell division cycle due to an abbreviated G1 phase. A
distinct set of transcription factors (Sox2, Oct4, Nanog) are
responsible for maintaining cell pluripotency and undifferenti-
ated phenotypes of cells. Suppression of Oct4 expression in
hESC leads to loss of pluripotency and induces expression of
differentiation markers specific for the trophectoderm [1,2] or
endoderm [3]. Transgene-mediated overexpression of Oct4
triggers differentiation of embryonic stem cells into endodermal
or mesodermal structures [4,5]. Experimental knockdown of
another transcription factor, Nanog, leads to hESC differenti-
ation towards embryonic or extraembryonic lineages, depending
on the experimental conditions and cell line-intrinsic determi-
nants [6,7,8]. Conversely to the effect of Oct4 overexpression,
the overexpression of Nanog promotes self-renewal of hESC in
the absence of any feeders [9]. Sox2 forms a dimeric complex
with Oct4 and mediates transcription of several stem-cell
specific genes, including their own promoter and that of Nanog
[10,11]. Transcription factors Oct4 and Sox2 are also involved
in reciprocal regulation of each other’s expression [12]. Despite
the effectiveness of the network of transcription factors in
promoting and maintaining pluripotency, their mode of action
remains unclear.
Microtubule-targeted agents like taxol, vinca alkaloids, colcemid
and nocodazole have been studied extensively in diverse types of
cell lines, including hESC cultures. These agents interfere with
microtubule polymerisation and cause arrest in the G2/M phase
of the cell cycle. Taxol binds to b-tubulin and stabilises
microtubules by making them rigid and less dynamic [13]. The
outcome of taxol treatment depends on the concentration used
and differs in different cell lines [14,15]. Nocodazole acts as a
microtubule destabiliser with the opposite effect of taxol. Still, it is
effective in disturbing microtubule dynamics and arresting cell
cycle progression at mitosis. Nocodazole has been used to arrest
hESC cells in the G2/M phase of the cell cycle. However, there is
no information regarding the effect of nocodazole on the
pluripotency markers Nanog and Oct4.
hESC lines are sensitive and any change of important
ingredients in the basic culture protocol or routine manipulation,
such as passaging and cryopreservation, could lead to various
degrees of differentiation and loss of pluripotency [16,17]. The
p160-Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor Y-
27632 is a promising agent in hESC culture methods, since it
improves cell proliferation [18,19,20] and recovery of frozen-
thawed variant pluripotent stem cell types, including hESC and
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karyotypically normal hESC and variant hESC without any
changes in cell cycle progression or morphology [24]. ROCK-2
inhibitor Y-27632 increases the expression of genes of stemness-
related integrins (aV, a6 and b1), which in turn increase ECM-cell
interaction [25]. Recently the ability of Y-27632 to inhibit myosin
light chain phosphorylation has been shown to be responsible for
increased cloning efficiency of hESC [26].
In this study we investigated the effect of nocodazole on hESC
pluripotency evaluated by the expression of markers Oct4, Nanog,
SSEA-3 and SSEA-4. We applied flow cytometry to analyse
distinct populations of cells in the different cell cycle phases. Using
this approach, we now report that the nocodazole treatment of
hESC results in loss of pluripotency markers Oct4 and Nanog.
After being released from nocodazole-caused arrest, the expression
of these pluripotency markers remained at the same low level, but
the cells were capable of continuing cell growth and up-regulating
the expression of SSEA-3 and SSEA-4 in the Nanog-expressing
cell population in the absence or presence of Y-27632. These
results show, that in hESC nocodazole reversible blocks cell
cycle, which is accompanied by irreversible loss of expression of
pluripotency markers Nanog and Oct4.
Materials and Methods
Ethics statement
This study was conducted using a commercially available
human embryonic stem cell line (WA09, National Stem Cell Bank,
Madison, WI, USA); no in vivo experiments in animals or humans
were performed and therefore approval from the ethics committee
was not necessary. Approval to isolate mouse embryonic
fibroblasts from the embryos of CD-1 mice (Animal Facility of
the Institute of Cell and Molecular Biology, Tartu, Estonia) was
obtained from the Committee for Experiments on Laboratory
Animals, Estonian Ministry of Agriculture.
Cell culture
Human ES cell line H9 (WA09, National Stem Cell Bank,
Madison, WI, USA) was cultured on MatrigelH (BD Biosciences,
San Jose, CA, USA) coated plates by using the mTeSR
TM1
maintenance medium (STEMCELL Technologies Inc, Vancou-
ver, Canada) according to the manufacturer’s specifications. The
medium was changed daily. After 7 days of growth colonies were
detached mechanically from the feeder cells with a micropipette
tip. After breaking the colonies by gentle pipetting, individual
hESC clumps were plated onto fresh MatrigelH coated plates.
Antibodies and reagents
Alexa-488-labelled anti-H3 antibodies specific for Ser10 phos-
phorylation, phospho-Ser28-specific anti-H3 antibodies, Alexa-
488-labelled anti-p53 antibodies and anti-cleaved caspase-3
antibodies were obtained from Cell Signaling Technology
(Beverly, MA). Alexa 647-labelled anti-Oct4 antibodies and their
isotype control were obtained from e-Bioscience. PE-labelled anti-
Nanog antibodies, Alexa 647-labelled anti-Gata 4 antibodies,
Alexa-647-labelled anti-SSEA-4 antibodies, Alexa-488-labelled
anti-SSEA-3 antibodies and their isotype controls were purchased
from BD Biosciences. Anti-p21
WAF1/CIP1 antibodies and another
anti-Oct4 antibodies were purchased from Santa Cruz (Santa
Cruz Biotechnology, San Diego, CA, USA). Nocodazole (Sigma-
Aldrich Chemicals, St. Louis, MO, USA) was dissolved and
diluted in DMSO (Sigma-Aldrich Chemicals). ROCK-2 inhibitor
Y-27632 was purchased from Tocris Bioscience (Bristol, UK).
Multivariate permeabilised-cell flow cytometry and cell
cycle analysis
Cell cultures were expanded for 5–6 days on 6-well plates and
treated with various concentrations of nocodazole or DMSO only
as a control, or grown without treatment at 37uCi n5 %C O 2
humidified atmosphere. After harvesting with 0.05% trypsin-
EDTA solution (PAA Laboratories, Linz, Austria) and washing
with PBS, single hES cell suspensions were fixed by using 1.6%
paraformaldehyde (PFA, Sigma-Aldrich) for 10 min at RT as
described for detection of intracellular phosphoproteins [27,28].
After that cells were washed and stained using a permeabilisation
buffer (Foxp3 Staining Buffer Set, e-Biosciences). Cells were
blocked using 2% goat serum in a permeabilisation buffer (15 min
at RT) and stained with appropriate antibodies or their isotype
controls for 30 min at RT. For cell cycle analysis the cells were
stained with DAPI (Cystain DNA, Partec GmbH, Mu ¨nster,
Germany). Flow cytometry data were acquired with FACSAria
using FACSDiva software (BD Biosciences). In some experiments
after trypsinisation, cells were first stained with anti-SSEA-3 and
anti-SSEA-4 antibodies and then fixed and permeabilised for
further staining with anti-Nanog antibodies.
The number of apoptotic cells was estimated after incubation of
an aliquot of collected living cells with PE-labelled Annexin-V (BD
Pharmingen) and with 7-AAD. Co-expression of Nanog and Oct4
in apoptotic cells was measured by using anti-cleaved caspase-3
antibodies followed with chicken anti-rabbit IgG antibodies
labelled with Alexa Fluor 488.
Cell permeabilisation, fixation, staining and data acquisition for
all samples were done on the same day.
Western blot analysis
Protein samples were electrophoresed on SDS polyacrylamide
gel (10%) and were transblotted (MiniTransblot Cell, Bio-Rad,
Hercules, CA) onto a polyvinylidene difluoride membrane
(Millipore, Billerica, MA). The membranes were probed with
rabbit anti-Nanog antibodies (Aviva Systems Biology, San Diego,
CA, USA), mouse anti-Oct4 antibodies (Santa Cruz Biotechnol-
ogy) and followed by horseradish peroxidase-conjugated goat anti-
rabbit or goat anti-mouse secondary antibodies. Expression of p53
was detected by incubating the membrane with rabbit anti-p53
antibodies (Cell Signaling Technology). Mouse anti-beta-actin
antibodies (Abcam, Cambridge, MA, USA) were used for loading
control. Binding of antibodies was detected with ECL reagent
(Western Lightning Plus-ECL, PerkinElmer Inc, Waltham, MA,
USA) and exposing the blots on X-ray films (Amersham
Biosciences).
Statistical analysis
A two-tailed paired t-test with a confidence interval of 95% was
used to analyse the data with GraphPad Prism 4 software. p value
less than 0.05 was considered significant. All results are presented
as mean 6 standard error. The distribution of cells in each phase
of the cell cycle was calculated using ModFit software.
Results
The effect of various concentrations of nocodazole on
hESC
To find out the most suitable concentration of nocodazole for
further experiments we first performed a dose-response experi-
ment. 50, 100 and 200 ng/ml nocodazole was added to the hESC
for 24 h. Then the cells were harvested and after staining with
appropriate antibodies analysed by flow cytometry for cell cycle
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Oct4. Nocodazole treatment caused morphological changes in
colonies: only multilayer dense areas of colonies survived. We
noticed progressive cell detachment and cell death (Figure 1).
DMSO-treated and untreated cell colonies expressed well-defined
borders and the colonies were so dense that individual cells could
not be distinguished.
The number of adherent cells decreased significantly after
nocodazole treatment compared to DMSO-treated or untreated
cells. Within the adherent cell population we detected a decrease
in the proliferating cell population caused by nocodazole
treatment (Figure 1 BC).
The distribution of cells in cell cycle phases changed after
nocodazole treatment. Whereas the untreated and DMSO-treated
cells were mostly in the S or in G1 phases, then after nocodazole
treatment we found fewer cells in the S phase and increased
number of cells in the G2/M phase (Figure 2A). Higher
concentrations of nocodazole resulted in a higher number of cells
in the G2/M phase and fewer cells in the G1 phase, according to
the cell cycle analysis with ModFit software (Figure 2A). The
expression of pluripotency markers Nanog and Oct4 in these cells
was evaluated by using simultaneous staining with appropriate
antibodies. We could detect a population of cells, which was
Nanog and Oct4 double-positive, but no single positive cell
population (Figure 3B). The expression of Nanog correlated with
the expression of Oct4. Nocodazole treatment caused a decrease
in the fraction of cells co-expressing Nanog and Oct4. When the
distribution of these double-positive cells in each cell cycle phase
was estimated, then a higher number of cells was found in the G2/
M phase (Figure 2C).
To find out whether nocodazole caused cell arrest in mitosis, we
evaluated the phosphorylation level of histone 3 (H3) at Ser10.
Phosphorylation of H3 was significantly increased after treatment
with nocodazole, compared to the treatment with DMSO as a
control (Figure 2D). Higher doses of nocodazole resulted in higher
phosphorylation levels of H3 at Ser 10. Cells with phosphorylated
H3 were in the G2/M phase of the cell cycle. When the lowest
concentration of nocodazole was used, we also found some cells
with phosphorylated H3 in the G1 phase (Figure 2D). There was a
good correlation between the phosphorylation levels of H3 and the
number of cells in the G2/M phase (Spearman non-parametric
correlation r=0.895; p,0.0001). We further evaluated whether
the cells with phosphorylated H3 expressed pluripotency markers
Nanog and Oct4. Nocodazole treatment caused an increase in the
phosphorylation level of H3, but co-expression of Nanog and Oct4
in these cells decreased when compared to DMSO-treated or
untreated cells (Figure 2E). In further experiments we used a low
dose (50 ng/ml) of nocodazole for several reasons: (a) it had the
lowest effect on cell survival; (b) the number of cells in the G2/M
phase increased and this was accompanied with an elevated level
of H3 phosphorylation; (c) cells expressing both Nanog and Oct4
were also detectable.
Nocodazole has a reversible effect on cell cycle arrest,
but not on pluripotency markers Nanog and Oct4
Since the number of attached cells decreased significantly after
nocodazole treatment, we then investigated whether the remaining
cells could proliferate after the release from nocodazole and
upregulate the expression of pluripotency markers Nanog and
Oct4. After 24 h of the nocodazole block the cells were intensively
washed with a growth medium and cultured for a further 24 h
with a fresh medium lacking nocodazole. To some cells a selective
ROCK-2 inhibitor (Y-27632), which improves survival of hESC
upon single-cell dissociation and enhances recovery from cryo-
preservation, was added. The short time period was chosen in
order to capture the initial changes in colony composition. After
nocodazole wash-out, the survival of cells decreased further, but
we detected no changes in the number of proliferating cells
(Figure 1BC). The morphologies of colonies grown in the presence
or in the absence of Y-27632 after nocodazole treatment were
compared to the colonies grown without any treatment. More
flattened morphology was noticed in the presence of Y-27632 than
in the absence of that at 24 h (Figure 1). The formation of small
colonies from dissociated cells was noticed in the presence of Y-
27632 in some plates.
Cell cycle profile returned to normal after 24 h of nocodazole
wash-out (Figure 4A): the number of cells in the S phase increased
and in the G2/M phase decreased and was comparable with
DMSO-treated or untreated cells (Figure 4A). After being released
from nocodazole arrest, the fraction of Nanog and Oct4 co-
expressing cells further decreased slightly (Figure 4B). A significant
decrease in the distribution of these double-positive cells in the G1
phase of the cell cycle was detected after removal of nocodazole
(Figure 4C). In comparison, DMSO treatment and subsequent
washout had no effect on the number of Nanog
posOct4
pos cells
(Figure 4B) and their distribution in cell cycle phases (Figure 4C).
Phosphorylation of H3 after removal of nocodazole decreased to
the level comparable with DMSO-treated cells and untreated cells
(Figure 5A). In nocodazole treated cells we detected a significant
decrease in a fraction of cells with phosphorylated H3 co-
expressing Nanog and Oct4 compared to DMSO-treatment or
untreated cells (Figure 5B). In addition, we evaluated the
phosphorylation of H3 at Ser28, which was comparable to the
results of phosphorylation of H3 at Ser10 (Figure 5CD). The
addition of Y-27632 to DMSO-treated or untreated cells had no
significant effect on the expression of pluripotency markers Nanog
and Oct4, cell cycle profile or expression of undifferentiation
markers SSEA-3 and SSEA-4 (Figure S1).
Expression of SSEA-3 and SSEA-4 in hESC treated with
nocodazole
We next investigated whether nocodazole treatment has any
effect on the glycosphingolipids on the cell surface. Thus the
expression of SSEA-3 and SSEA-4 was studied using two different
cell-staining procedures for analysis on a flow cytometer. First, the
cells were stained with antibodies specific to stage-specific
embryonic antigens SSEA-3 and SSEA-4 (monoclonal antibodies
MC631 and MC813-70, respectively), thereafter fixed, permeabi-
lised and stained with Nanog-specific antibodies. Another
approach was to fix cells first with 1.6% PFA and then cells were
co-stained with antibodies specific to SSEA-3, SSEA-4 and Nanog.
Both staining methods revealed two main cell populations: SSEA-
4
posNanog
pos cells and SSEA-4
posNanog
neg cells (Figure 6). These
cells, which expressed SSEA-4 at a high level, were also positive
for Nanog expression, while the cells with a low level of SSEA-4
expression had no detectable level of Nanog (Figure 6). The
Figure 1. Effect of nocodazole on hESC morphology. (A) Cells were treated with nocodazole 50 ng/ml, or with DMSO for 24 h or left untreated.
After nocodazole treatment, cells were washed with medium and grown in the presence or in the absence of Y-27632 (20 mM) for further 24 h.
(B) Number of adherent cells after nocodazole treatment compared to DMSO-treated cells and untreated cells. Scale bar=1000 mm (C) Proliferating
cells of adherent cells estimated by using DAPI staining.
doi:10.1371/journal.pone.0019114.g001
Effect of Nocodazole on hESC
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e19114Effect of Nocodazole on hESC
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19114majority of SSEA-3 expressing cells were positive for Nanog
expression in nocodazole-treated, DMSO-treated or untreated
cells. There was a positive correlation between expression of
SSEA-3 and SSEA-4: all the cells with high expression of SSEA-4
also expressed SSEA-3, which is in agreement with the previous
finding that both of these antibodies recognise a common epitope
(GL7) in hESC glycosphingolipids. In addition, SSEA-3 antibodies
bind to another epitope GL5, but SSEA-4 antibodies cross-react to
a different extent with other glycolipids and recognise another
epitope common in glycoproteins [29]. This could explain wider
and continuous distribution of SSEA-4 positive cells. SSEA-3
antibodies had a higher ability to bind to living cells (recognising
the internal structure of GL7 epitope), but SSEA-4-specific
antibodies to fixed cells (recognise the terminal structure of GL7
epitope) [29]. Unspecific binding of both SSEA-3 and SSEA-4
antibodies was lower, when living (non-fixed) cells were stained.
Fixation of cells even with 1.6% PFA considerably increased non-
specific binding with antibodies conjugated with Alexa Fluor 647.
It was also noted that non-specific binding in nocodazole-treated
cells was higher than in DMSO-treated or untreated cells. Since
the tendencies by using both methods were similar, we applied the
staining of fixed cells in the following experiments.
SSEA-3 and SSEA-4 expressions were studied in cells treated
with nocodazole and after its removal in the presence and absence
of Y-27632. As the number of Nanog
pos cells decreased after
nocodazole treatment and wash-out, we could detect a slightly
lower number of SSEA-4
pos Nanog
pos cells, but a higher number
of SSEA-4
posNanog
neg cells after treatment with nocodazole
compared to DMSO treatment (Figure 7, 8BC). When the
SSEA-4
pos Nanog
pos cell population was selected and investigated
for SSEA-3 expression, we found that the majority of cells were
SSEA-3 positive (Figure 7, 8D). Wider distribution of SSEA-4 and
SSEA-3 expression was noticed after 24 h treatment in the
presence of Y-27632 compared to its absence in nocodazole-
released cells. The removal of nocodazole resulted in an increase
of the mean fluorescence intensity of SSEA-4 and SSEA-3 in
SSEA-4
posNanog
pos and SSEA-3
posNanog
pos cell populations,
respectively, indicating up-regulation of SSEA-4 and SSEA-3
expression (e.g. epitope GL7 in globo-series glycolipids) in these
Nanog-expressing cells (Figure 7, 8BD). This effect was detectable
after 24 h growth in a fresh medium and the expression also
remained elevated at 48 h (data not shown). In some experiments,
nocodazole treatment for 16 h was used, which was not different
from treatment for 24 h. Thus, the expression of the Nanog
pluripotency marker decreased as a result of nocodazole
treatment, whereas the cells remained undifferentiated since the
SSEA-4-specific antibodies detected globo-series glycolipids on the
cell surface.
Expression of Gata-4 in nocodazole-treated hESC
We further asked whether the cells with non-detectable globo-
series glycolipids on the cell surface (SSEA-4 negative cell
population) were more prone to differentiation. The number of
differentiated cells was estimated by using antibodies specific to
Gata-4, since cells with a low level of Nanog expression have
reported to express Gata-4 [30]. The increased level of Gata-4
transcripts has been detected in the hESC upon Oct4 knockdown
[3]. The number of cells producing Gata-4 was rather low, ranging
from 0.4% to 3.9% (Figure 9), but increased Gata-4 expression
was noticed in nocodazole-treated and released cells, when
compared to DMSO-treated (and released) cells. To investigate
whether these Gata-4 expressing cells were in the G2/M phase, we
used co-staining with Gata-4 antibodies and phosphor-H3-specific
antibodies. hESC with Gata-4 expression had no phosphorylated
H3 and this result did not depend on the method of treatment
(Figure 9A). A similar low level of Nanog expression was noticed in
Gata-4-positive cells in all studied cell sets (Figure 9B).
Nocodazole induces apoptosis in hESC
hESC are especially sensitive to apoptosis, when dissociated into
single cells and when colony formation has been disrupted. The
number of apoptotic cells was estimated by staining living
adherent cells with Annexin V (Figure 10). Apoptosis was more
pronounced in nocodazole-treated cells and some apoptotic cells
were detected in DMSO-treated or untreated cells. After release
from nocodazole arrest, the rate of apoptosis decreased
(Figure 10B), being still higher than in DMSO-treated or
untreated cells. The addition of Y-27632 had no significant effect
on the number of apoptotic cells. Nocodazole caused necrosis and
death of cells to a similar extent as DMSO, but after the removal
of nocodazole, the survival of cells improved (Figure 10B). The
non-adherent cell population contained 30% of apoptotic cells and
70% of necrotic and dead cells, similarly in all studied cell sets.
Among non-adherent cells the higher number of necrotic and
dead cells was found in the G2/M phase after nocodazole
treatment compared to DMSO-treated cells or untreated cells
(data not shown).
To study whether the Nanog and Oct4 expressing cells were
more prone to apoptosis, we investigated the presence of cleaved
caspase-3, which characterises the late phase of apoptosis.
Nocodazole treatment caused the cleavage of caspase-3 in cells;
however, the majority of these cells were Nanog and Oct4 negative
(Figure 11). In DMSO-treated and untreated cells the number of
apoptotic cells with cleaved caspase-3 was low, but these cells were
mostly Nanog and Oct4 positive. Thus, in normal culture
conditions some Nanog-positive and Oct4-positive cells are more
prone to apoptosis. We found a good correlation between the
results of Annexin V staining and cleaved-caspase-3-positive cells
(p,0.02).
As the nocodazole-treatment resulted in a decrease of Nanog
and Oct4 expression in hESC, we next investigated whether the
level of p53 was upregulated in these cells. p53 is known to directly
regulate Nanog expression [31]. Nocodazole treatment increased
the level of p53 in hESC (Figure 12A). There were two
subpopulations of cells: p53
posNanog
neg and p53
posNanog
pos cell
subpopulations. A higher number of cells were found in the
subpopulation expressing p53 without Nanog expression in
nocodazole-treated cells. The release from nocodazole resulted
in a decrease of p53 expression, still being higher than in control
DMSO-treated or untreated cells (less than 2% of p53-positive
Figure 2. Effect of various concentrations of nocodazole on pluripotent hESC cells. H9 hESC were exposed to different concentrations of
nocodazole or DMSO for 24 h or left untreated. Fixed and permeabilised cells were stained with anti-H3-P-Ser10 (Alexa Fluor 488 conjugate), anti-
Nanog (PE), anti-Oct4 (Alexa Fluor 647) antibodies and with DAPI. For analysis cellular debris and doublets were excluded. (A) Cell cycle profile
determined by DAPI staining. Number of cells in each cell cycle phase as estimated by using ModFit software. (B) Flow cytometric analysis of Nanog
and Oct4 co-expressing cells and (C) their distribution in different cell cycle phases (stained with DAPI). (D) Phosphorylation of H3 at Ser10 in cellso f
different cell cycle phases and (E) expression of Nanog and Oct4 in these cells, which possessed phosphorylated H3. Results are representative of two
independent experiments.
doi:10.1371/journal.pone.0019114.g002
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posNanog
pos decreased significantly
after the removal of nocodazole and its replacement with a fresh
medium. There was no additional effect of Y-27632 on the
expression of p53. The results of flow-cytometry analysis were
confirmed by using the Western blot method, where the total
adherent cell population was analysed (Figure 12B).
p53 is known to regulate various cellular processes including
apoptosis, differentiation and genome integrity [32]. One of the
p53 targets is p21
WAF1/CIP1, the inhibitor of cell cycle phases in
the G1/S and G2/M and this protein has also been reported to be
upregulated as a response to nocodazole treatment in human non-
small cell lung carcinoma cell-line A549 [33]. Although the
expression of p21
WAF1/CIP1 was rather low, we found a 5-fold
increase in p21
WAF1/CIP1 protein expression in nocodazole-
treated cells compared to DMSO-treated or untreated cells. After
nocodazole wash-out, the expression of p21
WAF1/CIP1 was still
Figure 3. Characterisation of nocodazole-treated and released hES cells. Cells were arrested with 50 ng/ml nocodazole followed by
washing and expansion with fresh medium for further 24 h in the presence or in the absence of Y-27632. (A) Representative histograms of cell cycle
distribution. (B) FACS analysis of pluripotency markers Nanog and Oct4 (results shown as density plots) and (C) distribution of these Nanog
posOct
pos
cells in cell cycle phases. (D) Expression of Nanog and Oct4 in cell lysates detected by using Western blot assay. Beta-actin was used as loading
control. Results are representative of four independent experiments.
doi:10.1371/journal.pone.0019114.g003
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(A) Distribution of all cells in different cell cycle phases analysed by using ModFit software. (B) Summarising bar graph of flow cytometric analysis of
Nanog
posOct4
pos cells and (C) their distribution in cell cycle phases. Results are shown as mean 6 SEM of four independent experiments.
doi:10.1371/journal.pone.0019114.g004
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WAF1/CIP1 were mostly
in the G1 phase of the cell cycle (Figure 13).
Discussion
In this study we report that nocodazole treatment of hESC
causes a decrease in the expression of pluripotency markers Nanog
and Oct4, while the level of p53 becomes up-regulated and
accompanied by a high rate of apoptosis. After being released from
nocodazole treatment, the cells still express very little Nanog and
Oct4, although the cell cycle distribution becomes normal for ES
cells. We also found that the expression of SSEA-3 and SSEA-4
was up-regulated in Nanog-expressing cells after release from
nocodazole treatment.
Our findings are consistent with an earlier publication by
Becker et al showing the loss of pluripotency factor Oct4 in
nocodazole-synchronised cell cultures [34]. By using the flow
cytometry method we found that the number of cells co-expressing
both Nanog and Oct4 decreased significantly after nocodazole
treatment. Cell cycle analysis revealed that the distribution of
double-positive cells was higher in the G2/M phase, but lower in
the S phase compared to treatment with DMSO or untreated cells.
Figure 6. Detection of SSEA-3 and SSEA-4 on fixed or living hESC. hESC were first stained with anti-SSEA-3 (Alexa Fluor 488), anti-SSEA-4
(Alexa Fluor 647) antibodies and thereafter cells were fixed, permeabilised and stained with anti-Nanog (PE) antibodies (living cells). Alternatively, the
cells were stained after fixation with all three antibodies (fixed cells). For analysis cellular debris and doublets were excluded and DAPI-positive cells
were selected. Results are shown as density plots.
doi:10.1371/journal.pone.0019114.g006
Figure 5. Histone 3 phosphorylation in nocodazole-treated and released hESC. hESC were exposed to nocodazole as described in Figure 3.
(A) Phosphorylation of H3 at Ser 10 in the G2/M phase of cell cycle (density plots). (B) Expression of Nanog and Oct4 in cells with phosphorylated H3
as gated out in section A. (C) Phosphorylation of histone 3 at Ser10 or (D) Ser28. Results are shown as mean 6 SEM of four independent experiments.
doi:10.1371/journal.pone.0019114.g005
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PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e19114Figure 7. SSEA-3 and SSEA-4 expression in Nanog-positive cells. hESC were exposed to nocodazole as described in Figure 3. Cells were fixed with
1.6%PFAandstainedwithanti-SSEA-3(AlexaFluor488),anti-Nanog(PE),anti-SSEA-4(AlexaFluor647)antibodies andDAPI.Cells co-expressingSSEA-4and
Nanog were characterised for expression of SSEA-3. Results are shown as density plots and are representative of four independent experiments.
doi:10.1371/journal.pone.0019114.g007
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PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e19114The majority of untreated or DMSO-treated cells were in the S
phase, which is in agreement with an earlier report [35]. It has
been shown that hESC cells are already pre-committed in mitosis
to enter the next S phase in the absence of external stimuli [36].
Our results support this finding, since after the removal of
nocodazole the distribution of cells in cell cycle phases changed
towards an increased number of Nanog
posOct4
pos cells in the S
phase.
hESC undergo spontaneous apoptosis or anoikis (detachment-
induced apoptosis) upon cellular detachment and dissociation. We
noticed that intensive washing before adding a fresh growth
medium improved survival and decreased apoptosis in untreated
cells. Thus, the optimised culture conditions are essential to keep a
spontaneous rate of apoptosis at a low level. In this study we used
two different methods to estimate the rate of apoptosis. Annexin V
staining was used to characterise the early stage of apoptosis,
whereas a late stage of apoptosis was evaluated by detecting
cleaved caspase-3 in fixed and permeabilised cells. The latter
method allowed us to study the co-expression of Nanog and Oct4
in apoptotic cells. In nocodazole-treated cells cleaved caspase-3
was mostly detectable in Nanog and Oct4 negative cells. This was
different in control DMSO-treated or untreated cells, where only a
few cleaved caspase-3-positive cells co-expressed Nanog and Oct4.
Thus, in normal (untreated) hESC culture, cells expressing both
Nanog and Oct4 could be apoptotic. In nocodazole-treated cells it
might be that Nanog and Oct4 expression was already
downregulated in apoptotic cells. This can be caused by protein
p53, since we found elevated levels of p53 in nocodazole-treated
hESC. It has been shown earlier that p53 can directly bind to the
promoter regions of Oct4 and Nanog, thus influencing protein
expression levels [31]. In our experiments we could detect a
population of cells co-expressing Nanog and p53 after nocodazole
treatment, which has not been described earlier. This shows that
the cells can express both pluripotency marker Nanog and p53 at
the same time. Whether this is unique for human ESC should be
clarified in further studies. However, p53 obviously has other
functions in addition to downregulation of Nanog. For example,
after release from nocodazole arrest some Nanog-positive cells still
survived and the number of p53
posNanog
neg cells decreased. It is
therefore possible that the functional activity of p53 can be
downregulated by the components in the fresh medium itself after
the removal of nocodazole. Indeed, as recently shown, fibroblast
growth factor 2 (FGF2) in a fresh medium is essential to up-
regulate the level of Rem2 GTPase, which suppresses the
transcription activity of p53 [37]. In untreated hESC the level of
Rem2 GTPase is up-regulated and it is able to prevent protein
degradation during DNA damage [37]. The removal of nocoda-
zole block decreased apoptosis and p53 expression, but Nanog and
Oct4 expression remained at the same low levels as during
nocodazole arrest. The number of adherent cells and proliferating
cells decreased, pointing to the possibility that damaged cells were
not able to survive. Still, the majority of the survived adherent cells
were undifferentiated expressing high levels of SSEA-4 and low
levels of Gata-4.
Two different types of cell cycle arrest have been shown using
another microtubule-stabilising agent taxol in various carcinoma
cell lines [38,39,40]. Most of these cells were arrested in the pro-
metaphase, which triggered rapid cell death independent of p53.
The cells that could still pass mitosis were arrested in the
subsequent G1 phase by a p53-dependent mechanism [40]. In our
study the up-regulation of p21
WAF1/CIP1 was only found in a few
cells in the G1 phase, which could suggest that cells still passing
mitosis were arrested in the G1 phase. Induction of p21
WAF1/CIP1
has been related to the use of low concentrations of microtubule
stabilising agents and may assist cell death and contribute to cell
arrest in the G1 phase [41,33]. It has been shown that in non-
irradiated hESC cells (H1 cell line) p21
WAF1/CIP1 mRNA levels
are minimal and upon irradiation the level increases up to 300-
fold, the p53/p21
WAF1/CIP1 pathway gets activated and may
respond to DNA damage and mediate cell cycle arrest by blocking
DNA synthesis and allowing DNA repair or entry into apoptosis
[42]. Since p21
WAF1/CIP1 was detectable in very few cells it seems
that the mechanism involving the p53/p21
WAF1/CIP1 pathway
might be less abundant in hESC treated with nocodazole.
We also characterised the expression of SSEA-3 and SSEA-4
antigens on the surface of hESC by using two different staining
methods. We found that binding SSEA-3-specific monoclonal
antibodies to glycosphingolipids on the cell surface had a better
outcome in untreated and DMSO-treated cells, when living cells
were stained. Incubation with Nanog-specific antibodies after
fixing and permeabilisation of these stained cells allowed us to
confirm that the majority of SSEA-3-positive cells also express
Nanog. Thus, SSEA-3 antibodies can be used for sorting cells with
high levels of pluripotency markers Nanog and Oct4. This is in
agreement with a previous report showing that cells expressing
SSEA-3 differ from the SSEA-3 negative cell population by their
expression of Nanog and Oct [43]. SSEA-4-specific monoclonal
antibodies binding at the cells previously fixed and permeabilised
resulted in several populations, while the expression of Nanog was
detected in the population of SSEA-4
pos cells with high mean
fluorescent intensity. This finding is in line with the previous report
showing that SSEA-4 antibodies bind preferably to GL7 epitopes
in glycosphingolipids, which is the longest carbohydrate chain
among the glycolipids detected in hESC, and also to glycolipids
with shorter carbohydrate chains [29]. The latter ones are
frequently not detectable unless the cell membrane is disrupted
[44]. This could explain the different binding profile of SSEA-4
antibodies to fixed and permeabilised cells, since the epitopes
unreachable in living cells can be easily recognised after disruption
of the cell membrane. After the release from nocodazole arrest the
expression of both SSEA-3 and SSEA-4 increased, probably
reflecting the changes in cell surface glycolipids as the first event.
Flow cytometry analysis applied in this study allowed us to
characterise a single cell for several parameters at the same time,
which is a novel approach for characterisation of hESC. This
powerful method gives valuable results in understanding the
propagation of the cell cycle of hESC. However, for hESC the
flow cytometric analysis is more complicated compared to analysis
of other cell lines due to high non-specific binding, autofluores-
cence and a limited number of antibodies with high specificity.
Usually a single parameter flow cytometric analysis has been used
and the expression level of studied proteins has been reported to be
Figure 8. Characterisation of SSEA-4, SSEA-3 and Nanog expression in hESC released from nocodazole treatment. Summarising bar
graphs of flow cytometric analysis of cells stained as described in Figure 7. (A) Number of SSEA-4 expressing cells and SSEA-4
posSSEA-3
pos cells after
treatment with nocodazole and following release from nocodazole arrest in presence or absence of Y-27632. (B) Number of Nanog expressing and
SSEA-4-positive cells. Mean fluorescence intensity (MFI) of SSEA-4 expression of SSEA-4
posNanog
pos population. (C) Number of SSEA-4 expressing and
Nanog-negative cells. (D) Expression of SSEA-3 in SSEA-4
posNanog
pos cell population. MFI of SSEA-3 expression of SSEA-3
posNanog
pos population.
Results are shown as mean 6 SEM of four independent experiments.
doi:10.1371/journal.pone.0019114.g008
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PLoS ONE | www.plosone.org 13 April 2011 | Volume 6 | Issue 4 | e19114Figure 9. Expression of GATA-4 in hESC. H9 hESC were treated as described in Figure 3. Fixed and permeabilised cells were stained with anti-H3-
P-Ser10 (Alexa Fluor 488 conjugate), anti-Nanog (PE), anti-GATA-4 (Alexa Fluor 647) antibodies and DAPI. (A) Expression of GATA-4 and
phosphorylated H3 at Ser10 in hESC. (B) Number of Nanog and GATA-4 expressing hESC. Results are shown as density plots.
doi:10.1371/journal.pone.0019114.g009
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PLoS ONE | www.plosone.org 14 April 2011 | Volume 6 | Issue 4 | e19114Figure 10. Apoptosis of hESC treated with nocodazole. hESC were exposed to nocodazole as described in Figure 3. Adherent cells were
collected and stained with Annexin-V (PE conjugate) and 7-AAD. (A) Flow cytometric analysis of apoptotic cells (Annexin-V-positive cells) and necrotic
and dead cells (Annexin-V-positive and 7-AAD-positive cells). (B) Summarising bar graphs of flow cytometric analysis of apoptotic cells and (B)
necrotic and dead cells of four independent experiments.
doi:10.1371/journal.pone.0019114.g010
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PLoS ONE | www.plosone.org 15 April 2011 | Volume 6 | Issue 4 | e19114Figure 11. Expression of Nanog and Oct4 in apoptotic cells of hESC treated with nocodazole. hESC cells were treated with nocodazole as
described in Figure 3. Cells were fixed and stained with anti-Nanog (PE), anti-Oct4 (Alexa Fluor 647) and anti-cleaved caspase-3 (detected with anti-
rabbit IgG conjugated with Alexa 488) antibodies. (A) Expression of Nanog and (B) Oct4 in cleaved-caspase-3-positive cells. For analysis cellular debris
and doublets were excluded. Results are shown as contour plots and are representative of two independent experiments.
doi:10.1371/journal.pone.0019114.g011
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PLoS ONE | www.plosone.org 16 April 2011 | Volume 6 | Issue 4 | e19114Figure 12. Protein p53 upregulation in hESC cells as result of nocodazole treatment. Fixed and permeabilised cells were stained with anti-
p53 (Alexa Fluor 488) antibodies and anti-Nanog (PE) antibodies. (A) p53-positive cells and expression of Nanog in hESC. Results are shown as contour
plots. For analysis cellular debris and doublets were excluded. (B) Cell lysates were characterised for presence of p53 and Oct4 by using Western blot
assay. Detection of beta-actin was used as loading control.
doi:10.1371/journal.pone.0019114.g012
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explained by different antibodies used in various studies and by
different population selection criteria. In this study we used
selection of DAPI-positive cells, which were further analysed for
protein expression. In addition to that, we used at least two
different parameters (antigens) and applied density plots instead of
histograms, which can easily over-estimate the positive population
when there is no clear borderline between positive and negative
populations. Altogether, the optimised conditions for cell fixation
and antibody staining resulted in stricter population selection in
our study. Still, our results depend on the specificity and avidity of
the particular antibodies used in the experiment.
Nocodazole treatment is widely used to arrest cells in mitosis.
Here we show that the majority of cells in the G2/M phase
possessed phosphorylated H3 and obviously were arrested in the
M phase. Recently Teperek-Tkacz with co-workers have shown
Figure 13. Detection of protein p21
WAF1/CIP1 in nocodazole-treated cells. hESC were stained with anti-p21
WAF1/CIP1 antibody (detected with
anti-mouse IgG Alexa Fluor 647 conjugate) and DAPI. Results are shown as density plots and represent three independent experiments.
doi:10.1371/journal.pone.0019114.g013
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H3 phosphorylation-dephosphorylation at Ser10 differs from the
one observed in somatic cells by prolonged phosphorylation
following anaphase [45]. This was due to sustained kinase and not
lower phosphatase activity. De novo phophorylation of H3 at Ser10
started at the end of the S phase and was detectable during the G2
and the whole M phase including ana/telophase. Dephosphory-
lation of H3 at Ser10 started not earlier than at the G1 phase.
Phosphorylated H3 at Ser10 was present in pronuclei and
blastomere nuclei in early G1 phase, but not during early or
middle S phase [45]. In somatic cells, phosphorylation of H3 at
Ser10 appears first in late G2-interphase cells. Subsequently, the
phosphorylation of H3 at Ser10 spreads along the chromosomes, it
is completed at the prophase and is still evident in the metaphase
plate [46]. Using a low concentration of nocodazole we detected
phosphorylation of H3 at Ser10 in the G2/M and G1 phases. Why
in untreated and DMSO-treated cells the population in the G1
phase was not recognised can be explained by the low number of
cells with phosphorylated H3. In addition to Ser10 phosphoryla-
tion we also evaluated the phosphorylation of Ser28 of H3. The
results were comparable with those for phosphorylated Ser10. This
is in agreement with previous reports, where similar distribution of
H3 phosphorylation at Ser28 and Ser10 was observed, however,
the initiation of phosphorylations differed [47]. Our experimental
set-up could not give additional information to this question.
Nocodazole treatment increases cell detachment due to the
destabilisation of microtubules. We therefore used ROCK-2
inhibitor Y-27632 after nocodazole wash-out in order to improve
the survival, cell-cell interactions and cell attachment to MatrigelH.
After 24 hours of treatment with Y-27632 we detected the
formation of small colonies not visible on control plates without
the ROCK-2 inhibitor. The number of Nanog
posOct
pos, however,
remained at the same low level indicating that the expression of
Nanog and Oct4 could not be restored along with normalisation of
the cell cycle distribution similarly when Y-27632 was absent. The
addition of Y-27632 could not decrease the rate of apoptosis,
which is in contradiction with an earlier study, where Y-27632
markedly decreased the rate of dissociation-induced apoptosis of
hESC [48]. We found that the levels of p53 were still elevated after
nocodazole release and the addition of a fresh medium with Y-
27632. It might be that in the apoptotic cells signalling pathways
were already activated and the presence of Y-27632 could not
have any effect. We observed that in both DMSO-treated cells and
untreated cells the addition of Y-27632 increased the proliferation
of cells. It seems that Y-27632 preferably and selectively influences
the untreated (normal) cells, decreasing the survival of manipu-
lated cells.
The results of this study underline that in context of hESC it is
beneficial to have detailed characterisation of cells at the single cell
level whenever the cells have been manipulated. This in vitro
screening could be a valuable tool for estimating the effect of
medicinal agents or potential medicinal agents on the hESC in vivo.
Supporting Information
Figure S1 Effect of ROCK-2 inhibitor Y-27632 on
DMSO-treated and untreated cells. On day 5 after passaging
of cells, hESC were treated with DMSO (0.01%, same amount of
DMSO was added to cells with nocodazole solution in DMSO) or
left untreated. After 24 h cells were washed with fresh medium
and medium containing Y-27632 (20 mM) was added for
subsequent 24 h. Results were compared with hESC treated with
fresh medium for 24 h instead of Y-27632 containing medium.
Cells were stained as described in Figure 2 and in Figure 7.
(A) Cell cycle profile of hESC. (B) Expression of Nanog and Oct4
and (C) expression of SSEA-4 and Nanog in hESC. Results are
shown as contour plots and represent two independent experi-
ments.
(TIF)
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